JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB84654

Recombinant Human Rel B protein

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant Human Rel B protein is a Human Full Length protein, expressed in Baculovirus infected Sf9 cells, with >85%, suitable for SDS-PAGE.

View Alternative Names

Transcription factor RelB, I-Rel, RELB

1 Images
SDS-PAGE - Recombinant Human Rel B protein (AB84654)
  • SDS-PAGE

Unknown

SDS-PAGE - Recombinant Human Rel B protein (AB84654)

SDS-PAGE showing ab84654 at approximately 68kDa.

Key facts

Purity

>85% Densitometry

Expression system

Baculovirus infected Sf9 cells

Tags

His tag N-Terminus

Applications

SDS-PAGE

applications

Biologically active

No

Accession

Q01201

Animal free

No

Carrier free

No

Species

Human

Storage buffer

pH: 7 Preservative: 1.02% Imidazole Constituents: 25% Glycerol (glycerin, glycerine), 1.74% Sodium chloride, 0.82% Sodium phosphate, 0.0308% (R*,R*)-1,4-Dimercaptobutan-2,3-diol, 0.00174% PMSF

storage-buffer

style
left-column

Complementary Products

Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Primary Antibodies

AB309085

Anti-Rel B antibody [EPR26077-23] - BSA and Azide free

RabMAb|Recombinant

Western blot - Anti-Rel B antibody [EPR26077-23] - BSA and Azide free (AB309085)

  • 0
  • 0
Proteins & Peptides

AB237007

Recombinant Human p53 protein

Mass Spectrometry - Recombinant Human p53 protein (AB237007)

  • 0
  • 0
Proteins & Peptides

AB268982

Recombinant Human STAT3 protein (His tag)

SDS-PAGE - Recombinant Human STAT3 protein (His tag) (AB268982)

  • 0
  • 0
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column
style
left-column

Sequence info

[{"sequence":"","proteinLength":"Full Length","predictedMolecularWeight":null,"actualMolecularWeight":null,"aminoAcidEnd":0,"aminoAcidStart":0,"nature":"Recombinant","expressionSystem":null,"accessionNumber":"Q01201","tags":[{"tag":"His","terminus":"N-Terminus"}]}]
style
left-column

Properties and storage information

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-80°C
Appropriate long-term storage conditions
-80°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
False
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Rel B also known as RELB proto-oncogene is a member of the NF-κB family of transcription factors. This protein plays a significant role in regulating gene expression. Rel B has a molecular mass of approximately 68 kDa. It expresses in diverse tissues including lymphoid organs and epithelial cells. It generally resides in the cytoplasm and translocates to the nucleus upon activation.
Biological function summary

Rel B serves as a critical component of the alternative NF-κB signaling pathway. It often forms a complex with another NF-κB family member called p52. This complex controls the transcription of genes involved in the immune response cell survival and differentiation. Additionally Rel B contributes to the development of secondary lymphoid organs and modulation of immune responses.

Pathways

Rel B integrates into the non-canonical NF-κB signaling pathway also influencing the canonical pathway to a lesser extent. In the non-canonical pathway Rel B interacts with NIK and p100 to influence immune cell function. This involvement makes Rel B essential in processes like adaptive immunity and inflammatory responses. The protein p52 closely associates with Rel B aiding its activity in these pathways.

Rel B has connections to autoimmune diseases and certain cancers. Abnormal Rel B activity can lead to chronic inflammation and contribute to conditions like rheumatoid arthritis. In cancer its deregulation associates with lymphomas where it may interact with other NF-κB proteins like p50 and RelA affecting cell proliferation and survival. Understanding Rel B in these contexts could provide insights into therapeutic targets.
style
left-column

Specifications

Form

Liquid

Additional notes

Affinity purified.

style
left-column

General info

Function

NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-BMAL1 heterodimer in a CRY1/CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2/p52. Is required for both T and B lymphocyte maturation and function (PubMed : 26385063).

Post-translational modifications

Phosphorylation at 'Thr-103' and 'Ser-573' is followed by proteasomal degradation.

Subcellular localisation

Nucleus

style
left-column

Product protocols

style
left-column

Target data

NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-BMAL1 heterodimer in a CRY1/CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2/p52. Is required for both T and B lymphocyte maturation and function (PubMed : 26385063).
See full target information RELB
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com